ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer
Reports and Proceedings
Updates every hour. Last Updated: 6-Dec-2025 13:11 ET (6-Dec-2025 18:11 GMT/UTC)
EMBARGOED: A new study to be presented Dec. 6 at the 2025 American Society of Hematology (ASH) meeting reveals that even subtle disruptions in genome architecture can predispose individuals to lymphoma. This finding offers a new perspective on understanding and eventually treating blood cancers.
According to a new trial, patients with chronic lymphocytic leukemia show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received chemotherapy-based conditioning or total body irradiation (TBI), the standard conditioning regimen used before hematopoietic cell transplantation. The findings could allow more patients to avoid TBI and its associated long-term side effects.
ACCESS study reveals patients can safely receive stem cell transplants from unrelated donors with multiple genetic mismatches. A protective regimen acts as a “bridge,” preventing complications and boosting survival rates. Findings could make transplants accessible to nearly all patients with blood cancers, regardless of ancestry.
Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL) – the most common pediatric cancer – develop serious financial difficulties during their child’s treatment, including losing 25% or more of their household income and struggling to cover the costs of basic living expenses such as housing, food, and utilities.